Loading clinical trials...
Loading clinical trials...
Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)
Conditions
Interventions
Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]
Locations
1
Croatia
University Hospital for Infectious Diseases "Dr Fran Mihaljevic"
Zagreb, Croatia
Start Date
June 16, 2020
Primary Completion Date
April 16, 2021
Completion Date
May 15, 2021
Last Updated
November 12, 2020
NCT06082518
NCT07221162
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
University Hospital for Infectious Diseases, Croatia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions